04-08-2025
ZIM Laboratories secures marketing authorization in Australia for urology drug combination
By Aditya Bhagchandani Published on August 4, 2025, 13:55 IST
ZIM Laboratories Limited has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for its fixed-dose combination capsules of Tamsulosin Hydrochloride and Dutasteride. The approval was granted to ZIMTAS Pty Ltd, ZIM's wholly owned subsidiary in Australia, and marks the company's second marketing clearance in the region.
This milestone strengthens ZIM's presence in the regulated Australian market and aligns with its broader global expansion strategy. The combination drug is used to treat moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men, offering improved patient convenience by integrating two active agents into a single daily dose.
ZIM stated that this authorization will facilitate the product's commercial launch in Australia and bolster its regulatory filings across the APAC region and other global markets.
The company emphasized that this approval contributes to its growing urology segment and enhances its portfolio of differentiated generics through advanced drug delivery technologies.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
